DK2760475T3 - Fusionsproteiner til behandling af metaboliske lidelser - Google Patents

Fusionsproteiner til behandling af metaboliske lidelser Download PDF

Info

Publication number
DK2760475T3
DK2760475T3 DK12768999.0T DK12768999T DK2760475T3 DK 2760475 T3 DK2760475 T3 DK 2760475T3 DK 12768999 T DK12768999 T DK 12768999T DK 2760475 T3 DK2760475 T3 DK 2760475T3
Authority
DK
Denmark
Prior art keywords
pro
leu
fgf21
ser
gly
Prior art date
Application number
DK12768999.0T
Other languages
English (en)
Inventor
Brian R Boettcher
Shari L Caplan
Douglas S Daniels
Norio Hamamatsu
Stuart Licht
Stephen Craig Weldon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK2760475T3 publication Critical patent/DK2760475T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Claims (7)

1. Fusionprotein omfattende en FGF21 variant og en Fc region, hvor sekvensen for det nævnte protein er valgt fra en i det følgende angivet sekvens
2. Fusionsprotein ifølge krav 1 til anvendelse ved behandlingen af FGF21-associerede lidelser valgt fra gruppen bestående af obesitas, type 1 og type 2 diabetes mellitus, pancreatitis, dyslipidemi, ikke-alkoholisk fedtleverlidelse (NAFLD), ikke-alkoholisk steatohepatitis (NASH), insulinresistens, hyperinsulinemi, glucoseintolerance, hyperglykæmi, metabolisk syndrom, akut myocardial infarkt, hypertension, cardio-vaskulær lidelse, atherosclerose, perifer arteriel lidelse, slagtilfælde, hjertesvigt, koronær hjertelidelse, nyrelidelse, diabetiske komplikationer, neuropati, gastroparese og lidelser associerede med alvorlige inaktiveringsmutationer i insulinreceptoren.
3. Farmaceutisk sammensætning omfattende fusionsproteinet ifølge krav 1 og et farmaceutisk acceptabelt formuleringsmiddel.
4. Farmaceutisk sammensætning ifølge krav 3 til anvendelse ved behandlingen af en metabolisk lidelse.
5. Polynucleotid, som koder for fusionsproteinet ifølge krav 1.
6. Vektor indeholdende polynicleotidet ifølge krav 5.
7. Værtscelle, som bærer vektoren ifølge krav 6.
DK12768999.0T 2011-09-26 2012-09-26 Fusionsproteiner til behandling af metaboliske lidelser DK2760475T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161539280P 2011-09-26 2011-09-26
PCT/US2012/057384 WO2013049247A1 (en) 2011-09-26 2012-09-26 Fusion proteins for treating metabolic disorders

Publications (1)

Publication Number Publication Date
DK2760475T3 true DK2760475T3 (da) 2018-10-15

Family

ID=46970456

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17201957.2T DK3321276T3 (da) 2011-09-26 2012-09-26 Fusionsproteiner til behandling af metaboliske lidelser
DK12768999.0T DK2760475T3 (da) 2011-09-26 2012-09-26 Fusionsproteiner til behandling af metaboliske lidelser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK17201957.2T DK3321276T3 (da) 2011-09-26 2012-09-26 Fusionsproteiner til behandling af metaboliske lidelser

Country Status (41)

Country Link
US (5) US9006400B2 (da)
EP (2) EP2760475B1 (da)
JP (4) JP6186361B2 (da)
KR (1) KR102085605B1 (da)
CN (2) CN107266579B (da)
AP (1) AP2014007543A0 (da)
AR (2) AR088044A1 (da)
AU (1) AU2012316052A1 (da)
BR (1) BR112014007069B1 (da)
CA (1) CA2849464C (da)
CL (2) CL2014000736A1 (da)
CO (1) CO6920257A2 (da)
CR (1) CR20140140A (da)
CU (2) CU24314B1 (da)
CY (2) CY1120928T1 (da)
DK (2) DK3321276T3 (da)
EA (1) EA039633B1 (da)
ES (2) ES2689762T3 (da)
GT (1) GT201400055A (da)
HK (1) HK1251238A1 (da)
HR (2) HRP20211575T1 (da)
HU (2) HUE055584T2 (da)
IL (1) IL231533B (da)
IN (1) IN2014DN02043A (da)
JO (1) JO3476B1 (da)
LT (2) LT3321276T (da)
MA (1) MA35437B1 (da)
MX (1) MX350273B (da)
MY (1) MY166059A (da)
PE (2) PE20181159A1 (da)
PL (2) PL3321276T3 (da)
PT (2) PT2760475T (da)
RS (2) RS62341B1 (da)
SG (2) SG10201602339XA (da)
SI (2) SI2760475T1 (da)
TN (1) TN2014000109A1 (da)
TW (1) TWI593708B (da)
UA (1) UA113856C2 (da)
UY (2) UY34346A (da)
WO (1) WO2013049247A1 (da)
ZA (1) ZA201401700B (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299026B2 (en) 2006-07-25 2012-10-30 Lipoxen Technologies Limited Derivatisation of erythropoietin (EPO)
ATE554785T1 (de) 2007-03-30 2012-05-15 Ambrx Inc Modifizierte fgf-21 polypeptide und ihre verwendung
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PL3590949T3 (pl) 2010-10-01 2022-08-29 Modernatx, Inc. Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
KR102077721B1 (ko) 2011-07-01 2020-02-14 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사성 장애 및 질환의 치료를 위한 조성물, 용도 및 방법
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9006400B2 (en) 2011-09-26 2015-04-14 Novartis Ag Fibroblast growth factor-21-Fc fusion proteins
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
AU2012318752B2 (en) 2011-10-03 2017-08-31 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
LT2791160T (lt) 2011-12-16 2022-06-10 Modernatx, Inc. Modifikuotos mrnr sudėtys
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
JP6144355B2 (ja) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 化学修飾ｍＲＮＡ
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
NZ630484A (en) 2012-11-28 2017-04-28 Ngm Biopharmaceuticals Inc Compositions and methods for treatment of metabolic disorders and diseases
KR20230164238A (ko) 2012-12-27 2023-12-01 엔지엠 바이오파마슈티컬스, 아이엔씨. 담즙산 항상성의 조절 및 담즙산 질환 및 질병의 치료 방법
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
EP3057605A1 (en) 2013-10-18 2016-08-24 Novartis AG Methods of treating diabetes and related disorders
KR102178945B1 (ko) 2013-10-28 2020-11-13 엔지엠 바이오파마슈티컬스, 아이엔씨. 암 모델 및 관련 방법
HUE050279T2 (hu) 2014-01-24 2020-11-30 Ngm Biopharmaceuticals Inc Béta-klotho 2-es doménjéhez kötõdõ antitestek és azok alkalmazási módszerei
US20170065678A1 (en) * 2014-03-11 2017-03-09 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
AU2015277438B2 (en) 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
JP6949711B2 (ja) * 2014-10-23 2021-10-20 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド ペプチドバリアントを含む医薬組成物及びその使用方法
PT3412302T (pt) 2014-10-24 2021-06-09 Bristol Myers Squibb Co Polipéptidos de fgf-21 modificados e utilizações dos mesmos
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
KR20160088656A (ko) 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
KR20180035852A (ko) * 2015-08-03 2018-04-06 노파르티스 아게 Fgf21-연관 장애를 치료하는 방법
ES2871036T3 (es) 2015-11-09 2021-10-28 Ngm Biopharmaceuticals Inc Método para el tratamiento de trastornos relacionados con ácidos biliares
TW201731867A (zh) * 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
AU2017268469A1 (en) * 2016-05-20 2019-01-03 President And Fellows Of Harvard College Gene therapy methods for age-related diseases and conditions
MX2018014475A (es) * 2016-05-25 2019-05-23 Univ Texas Métodos y composiciones para el tratamiento de trastornos secretorios.
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN107759696A (zh) * 2016-08-19 2018-03-06 安源医药科技（上海）有限公司 人白介素7融合蛋白及其制备方法
AU2017315459B2 (en) 2016-08-26 2023-06-29 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
WO2018115401A1 (en) 2016-12-22 2018-06-28 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
US20220127322A1 (en) * 2017-03-14 2022-04-28 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
CN107050429B (zh) * 2017-04-01 2020-12-15 杭州生物医药创新研究中心 人成纤维生长因子21在制备用于治疗脑卒中药物中的应用
KR20200078425A (ko) * 2017-05-05 2020-07-01 트레포일 테라퓨틱스, 인크. 재조합 변형된 섬유아세포 성장 인자 및 이의 치료적 용도
CN109836504B (zh) * 2017-11-24 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
CN109929806B (zh) 2017-12-19 2020-05-08 北京吉源生物科技有限公司 一种表达glp1和fgf21的干细胞及其用途
CN111601613A (zh) * 2017-12-22 2020-08-28 诺华股份有限公司 用fgf21变体治疗代谢障碍的方法
CN110128525B (zh) 2018-02-08 2022-08-26 广东东阳光药业有限公司 Fgf21变体、融合蛋白及其应用
KR20210027426A (ko) 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 Fgf21 제제
CN111195234B (zh) * 2018-11-16 2022-08-26 鲁南制药集团股份有限公司 一种重组FGF21-Fc融合蛋白冻干粉制剂
EP3736574A1 (en) * 2019-05-07 2020-11-11 Atlas Antibodies AB A formulation comprising an isotope labeled fusion polypeptide
CN111944055B (zh) 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
CN112386575B (zh) * 2019-08-19 2023-03-21 鲁南制药集团股份有限公司 一种代谢调节融合蛋白的冻干制剂
CA3150224A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
US20230060422A1 (en) 2019-12-20 2023-03-02 Novartis Ag Combination treatment of liver diseases using integrin inhibitors
JP6924291B2 (ja) 2020-01-21 2021-08-25 シャープ株式会社 端末装置、方法、および、集積回路
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis
CN113265007B (zh) * 2021-06-10 2022-02-15 江南大学 一种治疗代谢疾病的融合蛋白及其制备方法和应用
CN115286705B (zh) * 2021-12-30 2024-05-10 长江大学 一种黄鳝成纤维细胞因子21重组蛋白及其制备方法和应用
WO2023245543A1 (en) * 2022-06-23 2023-12-28 Ampsource Biopharma Shanghai Inc. Uses of fgf21 fusion proteins

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
DE3889853D1 (de) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
AU1922101A (en) 1999-11-18 2001-05-30 Chiron Corporation Human fgf-21 gene and gene expression products
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
DK1616575T3 (da) 1999-12-23 2012-09-10 Zymogenetics Inc Fremgangsmåde til behandling af inflammation
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
WO2005037867A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
WO2005061712A1 (en) * 2003-12-10 2005-07-07 Eli Lilly And Company Muteins of fibroblast growth factor 21
DE602005016917D1 (de) * 2004-05-13 2009-11-12 Lilly Co Eli Fgf-21-fusionsproteine
DE602005016946D1 (de) * 2004-09-02 2009-11-12 Lilly Co Eli Muteine des fibroblasten-wachstumsfaktors 21
WO2006078463A2 (en) 2005-01-21 2006-07-27 Eli Lilly And Company Method for treating cardiovascular disease
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
CA2742043C (en) 2008-10-24 2014-11-25 Irm Llc Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues
PE20120358A1 (es) 2009-05-05 2012-04-26 Amgen Inc Mutantes fgf21 y usos de los mismos
CA2760674A1 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
US8324160B2 (en) * 2009-06-17 2012-12-04 Amgen Inc. Chimeric polypeptides and uses thereof
AU2010334974A1 (en) 2009-12-22 2012-07-12 Novartis Ag Tetravalent CD47-antibody constant region fusion protein for use in therapy
DE102010038140B4 (de) * 2010-10-13 2020-06-18 Hettich-Heinze Gmbh & Co. Kg Beschlag für eine Schiebetür
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
US9006400B2 (en) * 2011-09-26 2015-04-14 Novartis Ag Fibroblast growth factor-21-Fc fusion proteins
US20170065678A1 (en) 2014-03-11 2017-03-09 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling

Also Published As

Publication number Publication date
KR102085605B1 (ko) 2020-03-06
MA35437B1 (fr) 2014-09-01
PL2760475T3 (pl) 2018-11-30
CL2014000736A1 (es) 2014-10-03
EP3321276A3 (en) 2018-06-20
KR20140069250A (ko) 2014-06-09
US9006400B2 (en) 2015-04-14
SG10201602339XA (en) 2016-05-30
IL231533B (en) 2018-06-28
LT3321276T (lt) 2021-11-10
EP3321276A2 (en) 2018-05-16
CU20150171A7 (es) 2016-07-29
CN103945871B (zh) 2017-04-26
AR123908A2 (es) 2023-01-25
HRP20211575T1 (hr) 2022-02-04
US20150166622A1 (en) 2015-06-18
JP6186361B2 (ja) 2017-08-23
DK3321276T3 (da) 2021-10-25
PE20141551A1 (es) 2014-10-26
JP2022058546A (ja) 2022-04-12
US9266935B2 (en) 2016-02-23
JP2018023370A (ja) 2018-02-15
EP3321276B1 (en) 2021-07-28
AR088044A1 (es) 2014-05-07
AU2012316052A1 (en) 2014-04-17
JP6567613B2 (ja) 2019-08-28
NZ622998A (en) 2016-07-29
UY34346A (es) 2013-04-30
PL3321276T3 (pl) 2022-01-17
MX350273B (es) 2017-08-31
UY39119A (es) 2021-04-30
TW201326213A (zh) 2013-07-01
IL231533A0 (en) 2014-04-30
WO2013049247A1 (en) 2013-04-04
CU24314B1 (es) 2018-02-08
US20210386824A1 (en) 2021-12-16
CA2849464C (en) 2024-01-30
EP2760475A1 (en) 2014-08-06
JP2014534172A (ja) 2014-12-18
SG11201400538QA (en) 2014-06-27
ZA201401700B (en) 2015-01-28
CR20140140A (es) 2014-07-15
BR112014007069B1 (pt) 2020-12-15
BR112014007069A2 (pt) 2017-03-28
SI3321276T1 (sl) 2021-11-30
GT201400055A (es) 2017-09-28
SI2760475T1 (sl) 2018-10-30
JO3476B1 (ar) 2020-07-05
CN107266579B (zh) 2022-07-12
US20160193297A1 (en) 2016-07-07
JP2020007314A (ja) 2020-01-16
CO6920257A2 (es) 2014-04-10
CN107266579A (zh) 2017-10-20
RS62341B1 (sr) 2021-10-29
US20130079500A1 (en) 2013-03-28
HUE039857T2 (hu) 2019-02-28
HK1251238A1 (zh) 2019-01-25
ES2895080T3 (es) 2022-02-17
CL2016002215A1 (es) 2016-10-28
AP2014007543A0 (en) 2014-03-31
US11129874B2 (en) 2021-09-28
EA039633B1 (ru) 2022-02-18
HRP20181558T1 (hr) 2018-11-30
PT2760475T (pt) 2018-10-25
CA2849464A1 (en) 2013-04-04
CU24206B1 (es) 2016-10-28
LT2760475T (lt) 2018-10-25
US20180369332A1 (en) 2018-12-27
MY166059A (en) 2018-05-22
ES2689762T3 (es) 2018-11-15
TWI593708B (zh) 2017-08-01
RS57868B1 (sr) 2018-12-31
PE20181159A1 (es) 2018-07-19
EA201490695A1 (ru) 2015-10-30
PT3321276T (pt) 2021-10-27
MX2014003677A (es) 2014-04-30
US11944664B2 (en) 2024-04-02
IN2014DN02043A (da) 2015-05-15
EP2760475B1 (en) 2018-07-04
HUE055584T2 (hu) 2021-12-28
CY1124697T1 (el) 2022-07-22
JP7339372B2 (ja) 2023-09-05
CN103945871A (zh) 2014-07-23
US10076554B2 (en) 2018-09-18
TN2014000109A1 (en) 2015-07-01
UA113856C2 (xx) 2017-03-27
CY1120928T1 (el) 2019-12-11
CU20140034A7 (es) 2014-08-28

Similar Documents

Publication Publication Date Title
US11944664B2 (en) Fibroblast growth factor-21-Fc fusion proteins
US9023791B2 (en) Fibroblast growth factor 21 mutations
EP2764019B1 (en) Dual function proteins for treating metabolic disorders
AU2015202304C1 (en) Fusion proteins for treating metabolic disorders
AU2016202834A1 (en) Fusion proteins for treating metabolic disorders
Boettcher et al. Patent: Fusion Proteins for Treating Metabolic Disorders
NZ622998B2 (en) Fusion proteins for treating metabolic disorders